A family office based in the US has a focus on the social impact as an overall investment mandate. The firm aims to fund cutting-edge therapeutics companies, and is open to both early and later-stage assets. The firm will invest globally. The firm has an accelerator arm, for which the firm is seeking companies with pre-clinical and clinical therapeutics with a minimum initial investment of $1M-$10M, with the possibility of follow-on investments. The firm itself generally invests in companies with lead assets in Phase I – III clinical trials, and the amount of the allocation is based on the raise and pre-money valuation of the company.
The firm is looking for therapeutics companies, with a particular interest in biologics assets such as antibody-based technologies, cell and gene therapies. The firm mandate focused on regenerative and personalized medicine in oncology, neurodegenerative, orphan, and rare disease applications.
The firm will only consider companies that have more than two assets in the pipeline and experienced management team.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment